Muscarinic Receptors in the Human Brain: in Health and in Sickness

Grant number: 1045619 | Funding period: 2013 - 2015

Completed

Abstract

Schizophrenia is a severe mental illness, with sub-optimal treatment outcomes. New drugs are being designed to provide more effective treatment. To understand the effects of these drugs, we need to know which brain cells have the protein these new drugs target and which cells are affected in schizophrenia. Our project will determine the localisation of this drug target; this knowledge will help the development of better treatments for schizophrenia.

Related publications (11)

Scholarly works icon

Muscarinic receptor binding changes in postmortem Parkinson’s disease

C McOmish, G Pavey, C McLean, M Horne, B Dean, E Scarr

2017-02-01

Parkinson’s disease (PD) is a devastating disorder, affecting approximately 2% of people aged 60 and above. It is marked by progre..

Scholarly works icon

The distribution of muscarinic M1 receptors in the human hippocampus

E Scarr, MS Seo, TD Aumann, G Chana, IP Everall, B Dean

2016-11-01

The muscarinic M1 receptor plays a significant role in cognition, probably by modulating information processing in key regions suc..

Scholarly works icon

Understanding the pathophysiology of schizophrenia: Contributions from the Melbourne Psychiatric Brain Bank

B Dean, D Copolov, E Scarr

2016-11-01

The Melbourne Psychiatric Brain Bank came into existence 25 years ago. This review focusses on lines of research that have used ti..

Scholarly works icon

COMT genotype is associated with differential expression of muscarinic M1 receptors in human cortex

B Dean, E Scarr

2016-09-01

Catechol-O-methyltransferase (COMT) genotype has been associated with varying levels of cognitive functioning and an altered risk ..

Scholarly works icon

Validating reference genes using minimally transformed qpcr data: Findings in human cortex and outcomes in schizophrenia

B Dean, M Udawela, E Scarr

2016-05-20

Background: It is common practice, when using quantitative real time polymerase chain reaction (qPCR), to normalise levels of mRNA..

Scholarly works icon

Changes in BQCA allosteric modulation of [3H] NMS binding to human cortex within schizophrenia and by divalent cations

B Dean, S Hopper, PJ Conn, E Scarr

2016-05-01

Stimulation of the cortical muscarinic M1 receptor (CHRM1) is proposed as a treatment for schizophrenia, a hypothesis testable usi..

Scholarly works icon

Lower [3H]LY341495 binding to mGlu2/3 receptors in the anterior cingulate of subjects with major depressive disorder but not bipolar disorder or schizophrenia

CE Mcomish, G Pavey, A Gibbons, S Hopper, M Udawela, E Scarr, B Dean

2016-01-15

Introduction The glutamatergic system has recently been implicated in the pathogenesis and treatment of major depressive disorders..

Scholarly works icon

Evidence for impaired glucose metabolism in the striatum, obtained postmortem, from some subjects with schizophrenia

B Dean, N Thomas, E Scarr, M Udawela

2016-01-01

Studies using central nervous system tissue obtained postmortem suggest pathways involved in energy and metabolism contribute to t..

Scholarly works icon

Changes in cholinergic and glutamatergic markers in the striatum from a sub-set of subjects with schizophrenia

B Dean, N Thomas, CY Lai, WJ Chen, E Scarr

2015-12-01

Background/objectives: Having separated a sub-group of people with schizophrenia based on a marked loss of cortical [<sup>3</sup>H..

Scholarly works icon

The role of muscarinic receptors in the pathophysiology of mood disorders: A potential novel treatment?

WJ Jeon, B Dean, E Scarr, A Gibbons

2015-01-01

The central cholinergic system has been implicated in the pathophysiology of mood disorders. An imbalance in central cholinergic n..

Scholarly works icon

Potential molecular and cellular mechanism of psychotropic drugs

MS Seo, E Scarr, CY Lai, B Dean

2014-01-01

Psychiatric disorders are among the most debilitating of all medical illnesses. Whilst there are drugs that can be used to treat t..